{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:27:26Z","timestamp":1768292846851,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1208\/s12248-021-00573-1","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T22:02:51Z","timestamp":1616018571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses"],"prefix":"10.1208","volume":"23","author":[{"given":"Stein","family":"Schalkwijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarjinder","family":"Sahota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy B.","family":"Verheijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada F.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"12","key":"573_CR1","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-14-2685","volume":"21","author":"AG Schuller","year":"2015","unstructured":"Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, et al. The MET inhibitor AZD6094 (savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models. Clin Cancer Res. 2015;21(12):2811\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"573_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","volume":"9","author":"PR Gavine","year":"2015","unstructured":"Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015;9(1):323\u201333.","journal-title":"Mol Oncol"},{"issue":"36","key":"573_CR3","doi-asserted-by":"publisher","first-page":"57651","DOI":"10.18632\/oncotarget.10859","volume":"7","author":"RE Henry","year":"2016","unstructured":"Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, et al. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget. 2016;7(36):57651\u201370.","journal-title":"Oncotarget."},{"issue":"4","key":"573_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.celrep.2014.07.007","volume":"8","author":"RE Jones","year":"2014","unstructured":"Jones RE, Oh S, Grimstead JW, Zimbric J, Roger L, Heppel NH, et al. Escape from telomere-driven crisis is DNA ligase III dependent. Cell Rep. 2014;8(4):1063\u201376.","journal-title":"Cell Rep"},{"issue":"13 Supplement","key":"573_CR5","doi-asserted-by":"crossref","first-page":"CT031","DOI":"10.1158\/1538-7445.AM2019-CT031","volume":"79","author":"S Lu","year":"2019","unstructured":"Lu S, Fang J, Cao L, Li X, Guo Q, Zhou J, et al. Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring <em>MET<\/em> exon 14 skipping mutations. Cancer Res. 2019;79(13 Supplement):CT031\u2013CT (Abstract CT).","journal-title":"Cancer Res"},{"issue":"18","key":"573_CR6","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"H Jia","year":"2014","unstructured":"Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2, 3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014;57(18):7577\u201389.","journal-title":"J Med Chem"},{"issue":"11","key":"573_CR7","doi-asserted-by":"publisher","first-page":"S1768","DOI":"10.1016\/j.jtho.2017.09.377","volume":"12","author":"M Ahn","year":"2017","unstructured":"Ahn M, Han J, Sequist L, Cho BC, Lee JS, Kim S, et al. TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI. J Thorac Oncol. 2017;12(11):S1768 (OA 09.03).","journal-title":"J Thorac Oncol"},{"issue":"11","key":"573_CR8","doi-asserted-by":"publisher","first-page":"S1769","DOI":"10.1016\/j.jtho.2017.09.379","volume":"12","author":"J Yang","year":"2017","unstructured":"Yang J, Fang J, Shu Y, Chang J, Chen G, He J, et al. A phase Ib trial of savolitinib plus gefitinib for chinese patients with EGFR-mutant met-amplified advanced NSCLC. J Thorac Oncol. 2017;12(11):S1769 (Abstract OA 09.06).","journal-title":"J Thorac Oncol"},{"issue":"8","key":"573_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","volume":"6","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247\u201355.","journal-title":"JAMA Oncol"},{"issue":"3","key":"573_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han J-Y, Ahn M-J, Cho BC, Yu H, Kim S-W, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373\u201386.","journal-title":"Lancet Oncol"},{"issue":"16","key":"573_CR11","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1158\/1078-0432.CCR-18-1189","volume":"25","author":"HK Gan","year":"2019","unstructured":"Gan HK, Millward M, Hua Y, Qi C, Sai Y, Su W, et al. First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity. Clin Cancer Res. 2019;25(16):4924\u201332.","journal-title":"Clin Cancer Res"},{"key":"573_CR12","doi-asserted-by":"crossref","unstructured":"Sahota T, Dota CD, Vik T, Yan W, Verheijen RB, Walker S, et al. A randomized, double-blind, placebo- and positive-controlled, three-way crossover study in healthy participants to investigate the effect of savolitinib on QTc interval. Clinical Pharmacology in Drug Development. 2020;[In Press].","DOI":"10.1002\/cpdd.896"},{"key":"573_CR13","doi-asserted-by":"publisher","first-page":"104938","DOI":"10.1016\/j.ejps.2019.05.016","volume":"136","author":"Y Gu","year":"2019","unstructured":"Gu Y, Sai Y, Wang J, Yu M, Wang G, Zhang L, et al. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic\/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. Eur J Pharm Sci. 2019;136:104938.","journal-title":"Eur J Pharm Sci"},{"issue":"26","key":"573_CR14","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35(26):2993\u20133001.","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"573_CR15","doi-asserted-by":"publisher","first-page":"TPS9119","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9119","volume":"37","author":"GR Oxnard","year":"2019","unstructured":"Oxnard GR, Cantarini M, Frewer P, Hawkins G, Peters J, Howarth P, et al. SAVANNAH: A phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib. J Clin Oncol. 2019;37(suppl 15):TPS9119.","journal-title":"J Clin Oncol"},{"issue":"2","key":"573_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00656997","volume":"391","author":"OP Hamill","year":"1981","unstructured":"Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391(2):85\u2013100.","journal-title":"Pflugers Arch"},{"issue":"6","key":"573_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509\u201320.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"573_CR18","unstructured":"ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). ICH E14 guideline topic E14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005 [1\u201318]. Available from: https:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/the-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrh.html."},{"issue":"Pt 5","key":"573_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1042\/BST0351060","volume":"35","author":"A Dennis","year":"2007","unstructured":"Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007;35(Pt 5):1060\u20133.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"573_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/jpet.104.073692","volume":"312","author":"YA Kuryshev","year":"2005","unstructured":"Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005;312(1):316\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7083","key":"573_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463\u20139.","journal-title":"Nature."},{"issue":"1","key":"573_CR22","first-page":"23","volume":"13","author":"I Staudacher","year":"2010","unstructured":"Staudacher I, Schweizer PA, Katus HA, Thomas D. hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel. 2010;13(1):23\u201330.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"Suppl 1","key":"573_CR23","doi-asserted-by":"publisher","first-page":"I9","DOI":"10.1186\/1742-4690-7-S1-I9","volume":"7","author":"C la Porte","year":"2010","unstructured":"la Porte C. Inhibitory quotient in HIV pharmacology. Retrovirology. 2010;7(Suppl 1):I9\u2013I.","journal-title":"Retrovirology"},{"key":"573_CR24","unstructured":"FDA. In vitro metabolism- and transporter-mediated drug-drug interaction studies guidance for industry: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2017 [Available from: https:\/\/www.fda.gov\/media\/108130\/download]"},{"issue":"2","key":"573_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2125.2005.02546.x","volume":"61","author":"LE Friberg","year":"2006","unstructured":"Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol. 2006;61(2):177\u201390.","journal-title":"Br J Clin Pharmacol"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.2147\/OTT.S210365","volume":"12","author":"S Han","year":"2019","unstructured":"Han S, Fang J, Lu S, Wang L, Li J, Cheng M, et al. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report. Onco Targets Ther. 2019;12:7323\u20138.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"573_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3324\/haematol.2011.058776","volume":"97","author":"TD Kim","year":"2012","unstructured":"Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, et al. Clinical cardiac safety profile of nilotinib. Haematologica. 2012;97(6):883\u20139.","journal-title":"Haematologica."},{"issue":"8","key":"573_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","volume":"38","author":"RR Shah","year":"2015","unstructured":"Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit. Drug Saf. 2015;38(8):693\u2013710.","journal-title":"Drug Saf"},{"issue":"5","key":"573_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295\u2013316.","journal-title":"Drug Saf"},{"issue":"6","key":"573_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/bjc.2015.82","volume":"112","author":"JS Kloth","year":"2015","unstructured":"Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011\u20136.","journal-title":"Br J Cancer"},{"issue":"14","key":"573_CR31","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","volume":"18","author":"K Thornton","year":"2012","unstructured":"Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722\u201330.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"573_CR32","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","volume":"19","author":"D Kazandjian","year":"2014","unstructured":"Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014;19(10):e5\u201311.","journal-title":"Oncologist."},{"issue":"2","key":"573_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00280-017-3349-y","volume":"80","author":"DR Miles","year":"2017","unstructured":"Miles DR, Lacy SA, Wada DR, Milwee S, Yaron Y, Nguyen LT. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes. Cancer Chemother Pharmacol. 2017;80(2):295\u2013306.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"573_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.tranon.2018.12.009","volume":"12","author":"ST Kim","year":"2019","unstructured":"Kim ST, Lee S, Park M, Park SH, Park JO, Lim HY, et al. Combination of docetaxel plus savolitinib in refractory cancer patients: a report on phase I trial. Transl Oncol. 2019;12(4):597\u2013601.","journal-title":"Transl Oncol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00573-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T20:28:56Z","timestamp":1671654536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00573-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.S is an employee and shareholder of AstraZeneca, and reports personal fees from AstraZeneca outside of the submitted work. T.S. is a former employee and shareholder of AstraZeneca and a current employee of GlaxoSmithKline. R.B.V is a former AstraZeneca employee, current employee of Johnson and Johnson and holds shares in AstraZeneca, Johnson and Johnson and Chinook Therapeutics. A.H is an employee and shareholder of AstraZeneca. G.F.A is a former employee and shareholder of Astrazeneca and a current employee of UCB Pharma Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Matthew Rizk (matthew_rizk@merck.com) and Suresh Agarwal (suresh.agarwal@amgen.com)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Suggested Expert Reviewers"}}],"article-number":"46"}}